[HTML][HTML] Evaluation of the clinical and economic value of sofosbuvir/velpatasvir (SOF/VEL) in patients with chronic hepatitis C in Spain during the last 5 years
R Esteban, R Domínguez-Hernández… - Gastroenterología y …, 2024 - Elsevier
Objective Direct-acting antivirals for the treatment of hepatitis C virus (HCV) represented a
paradigm shift. In 2017, sofosbuvir/velpatasvir (SOF/VEL-Epclusa®) was approved, which …
paradigm shift. In 2017, sofosbuvir/velpatasvir (SOF/VEL-Epclusa®) was approved, which …